Pfizer presented Phase 3 results for Litfulo (ritlecitinib) in vitiligo, reporting significant improvements in skin pigment measures across two pivotal studies. The company’s daily pill, if approved, would compete against an existing topical standard in the U.S. market. The data were presented during the European Academy of Dermatology and Venereology annual meeting, supporting planned submissions to the FDA and EMA. The Phase 3 readouts matter because vitiligo remains an autoimmune condition with difficult-to-measure outcomes, where validated endpoints can define competitive differentiation. For pharma, the news reinforces the push toward oral immune-modulating therapies in dermatology, where treatment convenience and durability are central to payer and patient adoption.